Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
March 14, 2022 08:02 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress
March 01, 2022 16:04 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)
February 09, 2022 16:04 ET
|
Phathom Pharmaceuticals
Vonoprazan met the primary endpoint for all three dose levels (10 mg, 20 mg, 40 mg) taken on-demand, demonstrating faster and sustained relief of episodic heartburn as compared to placebo...
Phathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx Conference
November 23, 2021 16:00 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals to Participate in Two Upcoming Investor Healthcare Conferences
November 12, 2021 16:30 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates
November 08, 2021 08:00 ET
|
Phathom Pharmaceuticals
Two New Drug Applications (NDAs) for vonoprazan-based treatment regimens for H. pylori infection were accepted for filing by FDA with six-month Priority Review granted; PDUFA target action date of May...
Phathom Pharmaceuticals Withdraws Public Offering
October 27, 2021 21:47 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Announces Proposed Public Offering of 5,000,000 Shares of Common Stock
October 26, 2021 16:01 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting
October 24, 2021 15:30 ET
|
Phathom Pharmaceuticals
Data from Phase 3 PHALCON-HP trial highlighted in oral presentation and recognized with the ACG Governors Award for Excellence in Clinical ResearchPhase 1 population PK data abstract concludes the...
Phathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific Meeting
October 21, 2021 08:00 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...